Avricore Health Inc. (TSXV:
AVCR, OTC: AVCRF) (“Avricore Health” or the “Company”) is pleased
to announce it has signed a partnership agreement with Ellerca
Health Corp to utilize their respective technologies and services
to offer the most robust diabetes screening and management
solutions on the market for community pharmacy.
Avricore Health’s Objective is to make actionable health
information more accessible for everyone by creating the world’s
largest rapid testing network in pharmacy through HealthTab, its
turnkey point-of-care testing solution that effectively turns
pharmacies into diagnostic hubs (sometimes known as ‘Community
Diagnostic Centres’ or CDCs) and connects them on a single,
cloud-based platform.
Ellerca Health Corp’s mission is to improve patient care through
leading technologies and innovation. Through self-management of
chronic diseases thanks to a fully supportive digital program,
Ellerca Health allows patients to be in control of their own
treatment through their 360Care™ app. Working together with
patients in this way reduces the cost and time of reactionary
treatment and shifts the focus to preventative care by reducing and
eradicating symptoms of chronic conditions.
Ellerca Health’s 360Care™ is an app-based digital platform for
chronic disease management which is quickly growing its client base
of benefits providers and drug makers to support better patient
health outcomes.
Through mutual collaboration on a project-by-project basis, the
companies are committed to achieving their shared vision of
bringing technologies to community settings which prioritize
early-detection and screening, along with consistent management of
chronic diseases, like diabetes.
“We believe strongly that cooperation can enhance what we do,
and that of those we work with,” said Hector Bremner, CEO of
Avricore Health. “We’ve already identified several projects where
HealthTab™ and 360Care™ can work together to support patient needs
in pharmacy, and we look forward to continuing to work towards
collaborating on these efforts.”
“Working together with Avricore Health will allow our members to
have easy access to A1C testing at local pharmacies and improve the
speed of results,” said Daniel Yeboah, General Manager of Ellerca
Health. “By bringing critical health data to a patient’s mobile
device quickly and providing the coaching needed to understand the
risks, we can continue to move away from just treating disease and
support better health outcomes for people living with chronic
conditions like diabetes.”
The companies look forward to jointly pursuing efforts to bring
enhanced patient services in community pharmacy which utilize
HealthTab™’s unique diagnostics and data-management systems with
the ongoing coaching and support of 360Care™.
About Ellerca HealthBased in Toronto,
Canada, Ellerca Health is a digital health organization that uses
the integration of mobile technology, real human interaction,
artificial intelligence, and proven behavioral science to
revolutionize the personal experience and health outcomes of people
living with chronic disease. Ellerca Health's approach delivers
continuous fully integrated virtual care and support, raising the
bar in the digital therapeutics market.
Shifting the healthcare paradigm to engage and empower
consumers, Ellerca Health is transforming chronic disease
management, patient outcomes, and healthcare costs with its
360Care™ platform.
Driving 360Care™ is the core philosophy that people with chronic
health needs, when provided with true care and companionship,
quickly make the incremental behavioral changes needed to stop the
progression of their conditions.
For more information
visit www.EllercaHealth.com and www.360care.ca.
About HealthTab™ + RASTR
HealthTab™ is a turnkey point-of-care testing solution that
combines best-in-class point-of-care technologies with a secure,
cloud-based platform for tackling pressing global health issues.
With just a few drops of blood from a finger prick, the system
generates lab-accurate results on the spot and data is reported in
real time. The test menu includes up to 23 key biomarkers for
screening and managing chronic diseases, such as diabetes and heart
disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTab™ has also
recently added capabilities for bacterial and viral tests, such as
strep and COVID-19. The HealthTab™ network model is unlike anything
in pharmacy today. It gives knowledgeable and trusted pharmacists a
greater role in primary care delivery, while empowering patients to
take more control of their health. It also reduces costs and
waiting times and provides many potential revenue streams including
equipment leasing & consumables, direct access testing, disease
prevention & management programs, sponsored health programs,
decentralized clinical trials, real world data (RWD) sets, and
third-party app integration through API.
About Avricore Health Inc.
Avricore Health Inc. (TSXV: AVCR) is a pharmacy service
innovator focused on acquiring and developing early-stage
technologies aimed at moving pharmacy forward. Through its flagship
offering HealthTab™ (a wholly owned subsidiary), its mission is to
make actionable health information more accessible to everyone by
creating the world’s largest network of rapid testing devices in
community pharmacies.
Contact: |
|
|
|
Avricore Health Inc.Hector Bremner, CEO
604-773-8943info@avricorehealth.comwww.avricorehealth.com |
Ellerca Health IncDaniel
Yeboahdy@ellerca.comwww.EllercaHealth.com |
Cautionary Note Regarding
Forward-Looking Statements Information in this press
release that involves Avricore Health's expectations, plans,
intentions or strategies regarding the future are forward-looking
statements that are not facts and involve a number of risks and
uncertainties. Avricore Health generally uses words such as
"outlook," "will," "could," "would," "might," "remains," "to be,"
"plans," "believes," "may," "expects," "intends," "anticipates,"
"estimate," "future," "positioned," "potential," "project,"
"remain," "scheduled," "set to," "subject to," "upcoming," and
similar expressions to help identify forward-looking statements. In
this press release, forward-looking statements include statements
regarding: the completion of the placement and the expected timing
thereof and the Company's expected use of proceeds from the
placement; the unique features that the HealthTab™ platform offers
to pharmacists and patients. Forward-looking statements reflect the
then-current expectations, beliefs, assumptions, estimates and
forecasts of Avricore Health's management. The forward-looking
statements in this press release are based upon information
available to Avricore Health as of the date of this press release.
Forward-looking statements believed to be true when made may
ultimately prove to be incorrect. These statements are not
guarantees of the future performance of Avricore Health and are
subject to a number of risks, uncertainties and other factors, some
of which are beyond its control and may cause actual results to
differ materially from current expectations, including without
limitation: failure to meet regulatory requirements; changes in the
market; potential downturns in economic conditions; and other risk
factors described in Avricore's public filings. These
forward-looking statements speak only as of the date on which they
are made, and the Company undertakes no obligation to update them
publicly to reflect new information or the occurrence of future
events or circumstances, unless otherwise required to do so by
law.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy
Avricore Health (TSXV:AVCR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avricore Health (TSXV:AVCR)
Historical Stock Chart
From Apr 2023 to Apr 2024